DYRK

EHT 1610 is a highly potent and selective inhibitor of dual-specificity tyrosine-phosphorylation-regulated kinases (DYRK), exhibiting IC₅₀ values of 0.36 nM for DYRK1A and 0.59 nM for DYRK1B. EHT 1610 demonstrates significant antileukemic activity, associated with modulation of cell cycle progression and induction of apoptotic pathways in target cells.

ID-8 is a DYRK inhibitor. ID 8 also stimulates proliferation at a steady rate (observed in serum-free media supplemented with 10 μM over a 30 day period).

AZ191 is a potent and selective DYRK1B inhibitor with IC50 of 17 nM, about 5- and 110-fold selectivity over DYRK1A and DYRK2.

Mirk-IN-1 is a potent inhibitor of Dyrk1B(Mirk kianse) and Dyrk1A with IC50 of 68??48 nM and 22??8 nM respectively.

tBID is a selective inhibitor of homeodomain-interacting protein kinase 2 (HIPK2) with an IC50 of ?0.33 ?M.

GSK-626616 is a potent, orally bioavailable inhibitor of DYRK3 (IC50=0.7 nM).

Paprotrain is a cell-permeable inhibitor of the kinesin MKLP-2, inhibits the ATPase activity of MKLP-2 with an IC50 of 1.35 μM and a Ki of 3.36 μM and shows a moderate inhibition activity on DYRK1A with an IC50 of 5.5 μM.

LDN-192960 hydrochloride is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively.

LDN-192960 is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively.